Nicola Yallup is National Head of Business Development and Marketing (BD&M) at the NIHR
Clinical Research Network (CRN). She leads the national and international promotion of the
CRN, wider NIHR and UK ecosystem as a prime place for undertaking clinical research. Nicola
is passionate about partnership and growth, working with commercial and non-commercial
organisations and across the UK’s research infrastructure to attract research that enables
access to innovative treatments for patients.
Nicola has held a number of cross-NIHR roles including programme leadership for the NIHR
Digital Strategy and delivery of COVID-19 Vaccines Research. Prior to this she led change
delivery within both private and public sector organisations, notably NHS Digital, Ford Motor
Company and Citibank.
Nigel is responsible for Cancer Research UK’s early drug development activity, translating novel agent scientific programmes through to clinic. Currently, Nigel and his team at CR-UK Centre for Drug Development manage a diverse portfolio of ~16 novel agents at various stages of development from GMP production, regulatory preclinical studies, through to first-in-human, phase I and early phase II clinical trials. Nigel joined Cancer Research UK in May 2009, having previously worked in a variety of senior management roles in the pharma and biotech sectors
I am an experienced leader and people manager with experience in Alliance management, clinical operation, sample management, scientific and laboratory management. I have a track record of delivering studies, projects, process improvements, innovative solutions and cohesive, high performing teams.
I thrive on interacting and collaborating with clients and/or stakeholders and being able to use my creative mindset to understand and exceed their expectations.
Finally, I love a challenge, something to get my teeth into, and a chance to learn and develop.
Specialties: Alliance management, People management, coaching, resource management, stakeholder management, Project management, client communication, GLP, GCP, immunology, sample management, system development, process improvement/optimization
Having two sons diagnosed with a rare disease (MPSII) changes your perspective and priorities in life. Having spent over 20 years in construction, many of which were at Board level, Bob decided to pursue a career in the Charity sector. At first becoming a Trustee, then progressed to Managing Director and Group CEO of various patient organisations, supporting those living with rare diseases and complex needs. Bob wanted to bring together his family experiences of a “Rare life lived” and commercial attributes in order to improve the lives of those most marginalised in society whilst, at the same time, helping to create a more sustainable financial future for patient organisations both in the UK and globally. As well as being Group CEO of the MPS Society/Rare Disease Research Partners he is proud to serve as Vice Chair of the LSD Collaborative, Board Member of the worldwide International MPS Network, Acting Chair of the New Born Screening Collaborative and work as a patient representative for MPS in various global charitable access programs that provide a possible lifeline to treatments in selected areas of the world. These are not job roles, but a way of life!
Ameeta is a Research fellow at the University of Birmingham based at the Centre for Patient Reported Outcomes Research and the National Institute for Health and Care Research Applied Research Collaboration West Midlands (NIHR ARC WM) Public Health theme, ARC WM EDI lead, EDI Representative for the Public Health Research for Health Consortium of the NIHR School for Public Health Research, the University of Birmingham Institute for Applied Health Research (IAHR) EDI lead, and leads the IAHR EDI in Research working group.
I am an innovative senior change management professional with significant experience of end-to-end delivery on large complex projects and transformation programmes. I spent the first 20 years of my career in Banking, starting out in my home country of New Zealand before moving to Ireland and then onto the UK. Working in the same industry across multiple countries and cultures has given me a strong appreciation for the different life experiences and perspectives that individuals contribute.
Neelam has recently stepped down from being the CEO of MedCity, the life sciences cluster organisation for London, which plays a pivotal role in bridging industry, NHS and academia to boost innovation and economic growth. Neelam’s extensive experience spans the private, public and not-for-profit sectors. She has worked with the Association of British Pharmaceutical Industries, the European Innovative Medicines Initiative and collaborated with NHS England, NICE and Public Health England.
Neelam regularly supports companies with R&D, advising on the UK regulatory and access landscape, and is actively working to shape delivery of appropriate real estate infrastructure for life sciences companies. Other roles include seats on the advisory board of the Innovation Centre in Digital Molecular Technologies at the University of Cambridge, and she is a Non-executive director on the board of the Health Research Authority.
Oliver Buckley-Mellor is a Research Policy Manager at the Association of the British Pharmaceutical Industry. He has spent most of his career working on the policy environment for clinical research, having previously served as a Policy Advisor at Cancer Research UK. Oliver has an MA in Public Administration and Public Policy and a BA in History.
Marisa, MD, Internal medicine, is currently Honorary Professor at Imperial College London, Lecturer in pharmacogenomics at the University of Tor Vergata Rome, and member of the Editorial Board of Precision NanoMedicine Journal.
Former European Medicines Agency Senior Scientific Advisor, Marisa is expert in pharmaceuticals regulatory science with established professional track record in strategies for advanced and innovative health products pipelines. Liaison with regulators, sponsors, clinicians, patients and public health professionals, constitutes important elements of Marisa’s professional asset.
